TRUSOPT 2 %
DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 2 % · DIN 02216205 · ELVIUM LIFE SCIENCES
Health Canada status: CANCELLED POST MARKET
What is TRUSOPT?
TRUSOPT 2 % contains DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 2 %. It is listed in the Health Canada Drug Product Database under DIN 02216205, held by ELVIUM LIFE SCIENCES, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as cancelled post market, status dated 08-Dec-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRUSOPT used for?
Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02216205 |
|---|---|
| Brand name | TRUSOPT |
| Generic / active ingredient | DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 2 % |
| Manufacturer | ELVIUM LIFE SCIENCES |
| Strength | 2 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01EC03 DORZOLAMIDE |
| AHFS class | 52:40.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 08-Dec-2025 |
| Original market date | 1996-12-31 00:00:00 |
How is it administered?
Monotherapy: 1 drop in affected eye(s) 3 times daily. Adjunctive (with beta-blocker): 1 drop 2 times daily. If using multiple drugs, administer at least 10 minutes apart.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (standard storage usually 15-30°C, but not stated in text).
How is it supplied?
TRUSOPT: 5 mL dispensers. TRUSOPT Preservative-Free: 4 pouches of 15 x 0.2 mL individual unit dose pipettes.
Contraindications
Hypersensitivity to any ingredient; severe renal impairment (CrCl < 0.5 mL/s); concomitant use with oral carbonic anhydrase inhibitors.
Warnings and precautions
Sulfonamide-related reactions (e.g., Stevens-Johnson syndrome); risk of bacterial contamination; increased risk of corneal edema in patients with endothelial abnormalities.
Is DORZOLAMIDE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by JAMP PHARMA CORPORATION, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01EC03 DORZOLAMIDE. 3 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DORZOLAMIDE | 20 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02522373 |
| MED-DORZOLAMIDE | 2 % | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02457210 |
| SANDOZ DORZOLAMIDE | 2 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02316307 |
| APO-DORZOLAMIDE | 2 % | SOLUTION | APOTEX INC | APPROVED | DIN 02296055 |
| DORZOLAMIDE | 2 % | SOLUTION | MICRO LABS LIMITED | APPROVED | DIN 02528169 |
| DORZOLAMIDE | 2.0 % | SOLUTION | ALCON CANADA INC | CANCELLED PRE MARKET | DIN 02364999 |
| DORZOLAMIDE EYE DROPS BP | 2 % | SOLUTION | HIKMA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02489260 |
| DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC SOLUTION | 20 MG | SOLUTION | BAUSCH & LOMB INC | CANCELLED PRE MARKET | DIN 02395142 |
| DORZOLAMIDE PF | 2 % | SOLUTION | MICRO LABS LIMITED | APPROVED | DIN 02542110 |
| JAMP-DORZOLAMIDE | 2 % | SOLUTION | JAMP PHARMA CORPORATION | DORMANT | DIN 02453347 |
Who else supplies DORZOLAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DORZOLAMIDE appears in 1439 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.